eUpdate – Cancer of the Prostate Treatment Recommendations

eUpdate – Cancer of the Prostate Treatment Recommendations

Published: 28 September 2017. Authors: ESMO Guidelines Committee 

Clinical Practice Guidelines

This update refers to the Cancer of the prostate: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Parker C., Gillessen S., Heidenreich A. et al. Ann Oncol 2015; 26 (Suppl 5): v69-v77.

Section

Management of advanced/metastatic disease

Text update

Two phase III trials have compared ADT alone versus ADT plus abiraterone and prednisolone in men with metastatic, hormone-naive disease.  The LATITUDE trial included men with high risk metastatic disease.  Based on 406 events, abiraterone/prednisone improved overall survival (HR: 0.62, 95% CI: 0.51-0.76) [1].  The STAMPEDE trial included men with metastatic and non-metastatic disease.  Based on 446 events, abiraterone/prednisone improved overall survival (HR: 0.63, 95% CI: 0.52-0.76) [2].

Recommendations

  • ADT plus abiraterone/prednisone may be considered as first-line treatment for metastatic, hormone-naive disease [I, A].

References

  1. Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer. Fizazi et al. N Engl J Med. 2017 Jul 27;377(4):352-360
  2. Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy. James et al. N Engl J Med. 2017 Jul 27;377(4):338-351